Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2025; 16(6): 103685
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.103685
Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation
Jia-Hui Chen, Xiao-Chun Dai, Zi-Jiao Quan, Xin-Yu Liu
Jia-Hui Chen, Xin-Yu Liu, Department of Gerontology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121012, Liaoning Province, China
Jia-Hui Chen, Xiao-Chun Dai, Department of Gerontology, The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Disorder, Wenzhou 325000, Zhejiang Province, China
Zi-Jiao Quan, College of Life and Environmental Science, Wenzhou University, Wenzhou 325000, Zhejiang Province, China
Author contributions: Chen JH and Liu XY designed the experiments, conducted clinical data collection, conducted the collation, statistical analysis, and wrote the original manuscript and revised the paper; Dai XC and Quan ZJ performed postoperative follow-up and recorded the data; All authors read and approved the final manuscript.
Institutional animal care and use committee statement: All experimental procedures were approved by the Animal Ethics Committee of Jinzhou Medical University (No. 2023062) and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Yu Liu, PhD, Professor, Department of Gerontology, The First Affiliated Hospital of Jinzhou Medical University, No. 2 Section 5, Renmin Street, Guta District, Jinzhou 121012, Liaoning Province, China. lxy20240520@163.com
Received: December 20, 2024
Revised: March 21, 2025
Accepted: April 17, 2025
Published online: June 15, 2025
Processing time: 175 Days and 3.9 Hours
Core Tip

Core Tip: This study investigates the cardioprotective effects of erianin, a natural compound from Dendrobium chrysotoxum, in a type 2 diabetic mouse model. Erianin administration significantly reduced myocardial damage and improved metabolic parameters by activating the adenosine monophosphate-activated protein kinase/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway. These findings suggest that erianin may serve as a potential therapeutic agent to mitigate cardiac injury and inflammation in diabetes, offering new insights into managing diabetic cardiomyopathy.